Russia’s Enteromics Cancer Vaccine: Scientific success or global propagation?
Russia’s bold claim of 100% effective cancer vaccine takes global curiosity and caution. Produced on individual MRNA technology, anteromics can redefine the treatment of cancer as we know. But behind the headlines is a deep story of small tests, unanswered questions and expert debate.
We are living in a world that is still struggling with serious cancer data. However, a recent title of Russia has changed his head and raised hopes: an individual MRNA-based cancer vaccine called antigomics has reportedly shown 100% efficacy and security in the initial stage clinical trials.
If it proves to be 100% efficient, Job may mark a significant turn in the global fight against cancer. But it can be called as a real success, and how cautious is vigilant optimism as certainty?
Before we dive deep on the suspicion around the vaccine, what is anteromics, and how does it work?
The National Medical Research Radiology Center in Russia and the Angelhart Institute of Molecular Biology is based on the vaccine, MRNA technology-the same platform that operates the PFIZER and Modern Covid-19 vaccines.
However, the enteromics goes one step further: it is individual to the patient’s individual tumor profile.
How does this work?
“It is not a size-fit-all jab. Antaromics uses RNA extracted from the patient’s own tumor cells to teach their immune system how to attack cancer,” Dr. Yulia Mikhailova, a molecular oncologist, is a molecular oncologist.
In the early stage, which includes 48 patients of colorectal cancer, the vaccine performed the following conclusions:
- This showed 100% immune response activation
- There were no serious side effects
- About 60-80% tumor regression or stagnant progress was observed
- The vaccine promised early results in glioblastoma and melanoma test groups.
The results have inspired the Russian federal medical and biological agency (FMBA) to review fast-track regulatory, claiming the vaccine to assume what they believe is “clinical application”.
What makes this approach different?
Unlike traditional remedies to treat cancer, including chemotherapy or radiation, which attack healthy cells with people with cancer, the antromics are targeted and designed for minimally invasive.
The meaning of the initial promise has proved
Despite the striking title, major global experts are urging restraint.
In fact, phase I tests are mainly designed to evaluate protection and tolerance, not long -term results or comparative efficacy.
Dr. Says Bhatia, “No colleagues have been reviewed yet. As long as we have not seen raw data, biomarkers, progress-existence rates and overall existence beyond 6-12 months, this is a very promising but unproven intervention,” Dr. Bhatia says.
Global race for cancer vaccine
Russia is not alone in the race. The worldwide biotech firms, including Bontech (Germany), Modern (USA), and Curevac, are also trying individual MRNA cancer vaccines for tumors including pancreatic, melanoma and lung cancer. Some of these companies are already in phase II or III tests, giving them a start in terms of data strengthening and regulatory approval in markets such as European Union and America.
In this scenario, Russia’s declaration reflects the tremendous potential of MRNA platforms in oncology. But the global scientific community will accept these findings only once, when they become independently verified.
Does patients need to know
If you are a cancerous patient or careful of reading this report, then it is attractive to see it as a miraculous treatment. But experts urge patience.
Saying that, the technique behind antenomics is undeniably promising for patients suffering from cancer along with the community. The success of this vaccine can indicate a new era where cancer vaccines are individual, safe and more effective than traditional treatments.
The capacity of the antomics is not denied, and the results are impressive. But in the words of an experienced researcher: “Science proceeds not by press release but by published data,” AIIMS Delhi Professor of Oncology in Delhi. Vikram Chandra says. “If these results are under colleague review and multisaver phase III tests, we can be on the verge of a revolution. Till then, it is one of the most promising lead and is definitely not a confirmation.”